Iki Seiko, Usuki Kensuke, Iijima Kimiko, Urabe Akio
Division of Hematology, NTT Kanto Medical Center.
Rinsho Ketsueki. 2005 Apr;46(4):261-8.
We evaluated the efficacy and long-term outcomes of immunosuppressive therapy (IST) in 50 adult patients with aplastic anemia at a single institution. Twenty-one patients who had not responded to the first course of IST or relapsed after the initial response to IST were retreated with the second course of IST with antithymocyte globulin. The response and relapse rate of the initial IST were 76.7% and 23.3%, respectively. The response rate of salvage IST was 61.9%. Overall survival at 10 years was 84.0%. Failure-free survival at 10 years was 62.0%. Clonal or malignant diseases developed in 2 patients. Early deaths due to bleeding or infection were observed only in elderly patients. We conclude that most patients with aplastic anemia treated with IST show hematologic improvement and excellent long-term survival.
我们在一家机构评估了免疫抑制治疗（IST）对50例成年再生障碍性贫血患者的疗效和长期结局。21例对首个IST疗程无反应或在对IST初始反应后复发的患者接受了含抗胸腺细胞球蛋白的第二个IST疗程治疗。初始IST的缓解率和复发率分别为76.7%和23.3%。挽救性IST的缓解率为61.9%。10年总生存率为84.0%。10年无失败生存率为62.0%。2例患者发生了克隆性或恶性疾病。仅在老年患者中观察到因出血或感染导致的早期死亡。我们得出结论，大多数接受IST治疗的再生障碍性贫血患者血液学得到改善，且长期生存良好。
